Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Opportunities for immunotherapy
- Cancer immunity cycle
- Many points for therapeutic intervention
- Four dominant approaches to immunotherapy
- Cytotoxic antibodies
- Antibiotic-drug conjugates in trials
- Currently approved mAb for cancer
- Cytotoxic antibodies: mechanisms of action
- Cytotoxic antibodies: Rituximab (a-CD20)
- Passive CTL immunotherapy
- CAR T cells: engineered targeting
- CAR T cells: Kymirah (a-CD19)
- Checkpoint blockade: anti-CTLA4
- Checkpoint blockade: Ipilimumab (a-CTLA-4)
- Checkpoint blockade: anti-PD1 and anti-PDL1
- Nivolumab (a-PD1) and Durvalumab (a-PDL1)
- Not all patients respond to treatment
- Vaccination
- Vaccination: therapeutic vaccines
- Cell based vaccine (DC)
- Therapeutic cancer vaccine: Sipuleucel-T
- Tumour specific neoantigens (1)
- Tumour specific neoantigens (2)
- Current immunotherapy development landscape
- Common toxicities
- Prospects for immunotherapy
- Thank you
Topics Covered
- Opportunities for immunotherapy
- Cytotoxic antibodies
- Monoclonal antibodies
- CAR T cells: engineered targeting
- Checkpoint blockade treatment
- Therapeutic vaccines
- Tumour specific neoantigens
- Current immunotherapy development landscape
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Elliott, T. (2021, September 30). Cancer immunotherapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/LGBZ2469.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tim Elliott has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Molecular Basis of Cancer
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Tim Elliott.
I'm the Kidani Professor of Immuno-oncology.
I work at the University of Oxford in the UK.
In this lecture, I'm going to give a brief introduction
to the basic principles of cancer immunotherapy.
I recommend you listen to an accompanying lecture in the same series here
on cancer immunology and this would serve as
a good primer to the lecture you're about to see now.
0:25
This cartoon describes in very basic terms,
the relationship between our immune system and a growing tumor.
We know that it's possible to prime T-cells to tumor antigens.
Those T-cells, when they become activated,
can home into the site of tumor development in a tissue where they
join other tissue-resident lymphocytes and together, these can kill tumor cells.
And that this process of tumor ablation can balance any cell division that's
occurring in tumor cells and a period of so-called tumor equilibrium can ensue.
We also know, however,
that tumors can escape this immune attack either by
inducing functional exhaustion in T-cells or by inducing
any immunosuppressive tumor microenvironment by attracting suppressive cells to
the microenvironment or by
reprogramming tissue-resident cells to become immunosuppressive.
Well, the tumors can simply lose the ability to
present and process antigens to those T-cell.
They escape simply because they become invisible and this then leads
to a period of tumor progression which is clinically potentially lethal.
Now, each one of these stages is a potential target for immunotherapy.
I'll go through these in turn throughout my lecture.